Tags:LifeScience
Lead candidate AMC303 is being developed as a treatment for patients with advanced and metastatic squamous tumors, e.g. head and neck cancer, esophageal cancer, cervical cancer, and lung cancer. AMC303 has a high specificity for inhibiting CD44v6, a co-receptor required for signaling through multiple cellular pathways (c-Met, VEGFR-2, RON)
Member count: 1-10
Total raised: $8.392295M
Founded date: 2011

Investors 1

DateNameWebsite
-LBBW Ventu...lbbwvc.de

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
31.08.2017Grant$2.084142M-finsmes.co...
14.12.2016Series B$6.308153M-finsmes.co...

Mentions in press and media 4

DateTitleDescriptionCategoryAuthorSource
31.08.2017amcure Rec...amcure, a German biopharmaceut...Germany-finsmes.co...
15.12.2016Amcure rai...German oncology biotech Amcure...Biotech-fiercebiot...
14.12.2016Term Sheet...SAN DIEGO, DIVERSITY AND LEONA...--fortune.co...
14.12.2016amcure Rai...amcure, an Eggenstein-Leopolds...Germany-finsmes.co...